What do systematic reviews say?

Intervention not reported

The review found no eligible studies for this question.

• Surgery for the treatment of obesity in children and adolescents 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 85 participants
  Very low

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

Recombinant human thyrotropin‐aided radioiodine probably leads to higher hypothyroidism compared with radioiodine (moderate certainty).

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  RR 2.53 [1.52, 4.2]
  6 studies · 321 participants
  Moderate

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

Recombinant human thyrotropin‐aided radioiodine showed no clear difference in adverse events compared with radioiodine (low certainty).

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  RR 1.24 [0.94, 1.63]
  6 studies · 321 participants
  Low

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 268 participants
  Moderate

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 28 participants
  Very low

Recombinant human thyrotropin‐aided radioiodine vs radioiodine

The review found no eligible studies for this question.

• Recombinant human thyrotropin (rhTSH)‐aided radioiodine treatment for non‐toxic multinodular goitre 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: insulin detemir vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  4.97 [0.79, 31.38]
  9 studies · 3334 participants
  Moderate
• (Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
  Peto OR 0.74 [0.2, 2.65]
  8 studies · 2328 participants
  Low

Insulin glargine vs NPH insulin

Summary of findings: insulin glargine showed no clear difference in severe hypoglycaemia (n/N) Definition: symptomatic hypoglycaemia… compared with NPH insulin (moderate certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 0.84 [0.67, 1.04]
  9 studies · 2350 participants
  Moderate

Insulin glargine vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 585 participants
  Low

Insulin glargine vs NPH insulin

Summary of findings: insulin glargine showed no clear difference in severe nocturnal hypoglycaemia (n/N) Definition: severe… compared with NPH insulin (moderate certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 0.83 [0.62, 1.12]
  6 studies · 1893 participants
  Moderate

Insulin glargine vs NPH insulin

Summary of findings: insulin glargine showed no clear difference in serious adverse events (n/N) compared with NPH insulin (moderate certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 1.08 [0.63, 1.84]
  8 studies · 2229 participants
  Moderate

Insulin glargine vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 2285 participants
  Moderate
• (Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  16 studies · 5809 participants
  Low

Summary of findings: insulin detemir vs insulin glargine

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 763 participants
  Low

Summary of findings: insulin detemir vs insulin glargine

The review found no eligible studies for this question.

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: insulin detemir vs insulin glargine

It is very uncertain whether summary of findings: insulin detemir changes severe hypoglycaemia (n/N) Definition: hypoglycaemia requiring third… compared with insulin glargine (very low certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 0.59 [0.13, 2.63]
  2 studies · 763 participants
  Very low

Summary of findings: insulin detemir vs insulin glargine

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 443 participants
  Low

Summary of findings: insulin detemir vs insulin glargine

It is very uncertain whether summary of findings: insulin detemir changes severe nocturnal hypoglycaemia (n/N) Definition: severe… compared with insulin glargine (very low certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 0.55 [0.06, 5.12]
  2 studies · 763 participants
  Very low

Summary of findings: insulin detemir vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 870 participants
  Low
• (Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 873 participants
  Very low

Summary of findings: insulin detemir vs insulin glargine

Summary of findings: insulin detemir showed no clear difference in serious adverse events (n/N) compared with insulin glargine (low certainty).

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  RR 1.72 [0.91, 3.28]
  2 studies · 763 participants
  Low